NOV looking pretty darn interesting
Highlights: Contract wins for the Technology Division. Flexepin has gained strong market traction with commercial operations underway in Canada and Australia. Cash on hand (excluding client funds) was at $5.6m at end of 3QFY16. Total revenue in the nine months to 31 March 2016 of $4.1m, up 32% compared with $3.1m for entire FY15. Novatti well funded to reach key commercial milestones as outlined in its December 2015 prospectus. Group revenue will become more recurring in nature as the Company increases its SaaS and financial processing transaction revenues. Management expects to announce significant updates for Flexepin and TransferBridge divisions in the short-term
- Forums
- ASX - Day Trading
- Daytrading May 30 afternoon
NOV looking pretty darn interesting Highlights: Contract wins...
-
- There are more pages in this discussion • 132 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online